Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    alzheimer | elan
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: ELND005;   Drug: Placebo
2 Enrolling by invitation A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Group 1 ELND005;   Drug: Group 2 ELND005

Indicates status has not been verified in more than two years